Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 103   

Articles published

SLXP 172.81
price chart
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
What: Shares of Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P Capital IQ, after the ...
Related articles »  
Salix Pharmaceuticals, Ltd. (SLXP) Attracts Endo International's (ENDP) Attention
... is in the race to acquire Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), anonymous sources told Reuters. Endo, which focuses on pain management drugs, sent several letters to Salix, maker of drugs for bowel diseases, only to be rebuffed on many accounts.
Valeant Said to Secure Salix Financing, Closing In on Offer  Bloomberg
Bullish Salix Analyst Says Shares are Fairly Valued Absent a Deal  Wall Street Journal (blog)
Salix Pharmaceuticals, Ltd. (SLXP) Q1 Earnings Preview: What To Expect
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) is scheduled to announce its financial results for the first quarter of fiscal year 2015 (1QFY15) on Thursday, May 7 after the markets close.
Here's Why Salix Pharmaceuticals, Ltd. Executives Received Millions Even After ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) has paid as much as $46 million combined to two of the top executives who left the company following the accounting scandal late last year.
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International ...  Nasdaq
Salix Pharmaceuticals Given New $173.00 Price Target at Mizuho (SLXP)  Dakota Financial News
3 Pharma Companies Competing To Acquire Salix Pharmaceuticals, Ltd. : Who ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a Raleigh-based specialty pharmaceutical company focusing on innovative treatments for various gastrointestinal disorders, has been the top potential takeover target for some of the major pharmaceutical ...
Endo said to be jousting with Valeant, Shire to win Salix  FiercePharma
Benzinga's Weekend M&A Chatter  Benzinga
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company") (NASDAQ GS: SLXP) regarding possible breaches of fiduciary duties and other ...
Salix Pharmaceuticals, Ltd.-Valeant Pharmaceuticals Intl Inc Deal Gets Top ...  Bidness ETC
Canadian drug maker Valeant buying Salix Pharmaceuticals for $10B
Stock Analysis on Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)
[Bloomberg] Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)(TREND ANALYSIS), Two top executives at Salix Pharmaceuticals Ltd. who left after accounting errors at the company will walk away with a combined $46 million, following the company's sale to ...
Sale prospects of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
The Jefferies increased the figure of target price which they had put on Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), from $123 to $138.
Salix Pharmaceuticals, Ltd Downgraded At UBS
UBS downgrades Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) stock from a Buy to a Hold rating, but increases its price target from $144 to $158.
Salix Pharmaceuticals Moves Up In Market Cap Rank, Passing Computer ...  Nasdaq
Deadline in Lawsuit for Investors in Salix Pharmaceuticals, Ltd. (SLXP) Shares ...
Furthermore, the plaintiff alleges that Salix Pharmaceuticals, Ltd's reserves for outstanding inventory were understated and, because of this understatement, its reported quarterly and annual net revenue and earnings per share figures were overstated ...
Robbins Arroyo LLP: Salix Pharmaceuticals, Ltd. (SLXP) Misled Shareholders ...  GlobeNewswire (press release)
Salix Pharmaceuticals: What Scares Me Most About Its High Inventory & ...  Seeking Alpha (registration)
Related articles »